XPNPEP2

XPNPEP2 encodes a GPI-anchored, membrane-bound Xaa-Pro aminopeptidase (aminopeptidase P) that cleaves N-terminal Xaa-Pro bonds in peptide substrates including bradykinin and neuropeptide Y, functioning as a key enzyme in bradykinin catabolism (PMID:10894934, PMID:17223229). The gene's promoter is regulated by an upstream enhancer containing the C-2399A polymorphism that differentially binds HNF4; the low-activity A allele reduces plasma aminopeptidase P activity and predisposes to ACE inhibitor-induced angioedema, with sex- and race-dependent penetrance (PMID:16175507, PMID:21898657, PMID:20625347). Beyond peptidase activity, XPNPEP2 is essential for endothelial angiogenesis: it physically interacts with the mitochondrial carrier SLC25A6 and protects it from SIAH1-mediated proteasomal degradation, thereby maintaining mitochondrial ATP production and respiratory chain integrity; XPNPEP2 deletion in mice causes vascular pathology, impaired wound healing, and reduced tumor growth (PMID:41573684).

1. 2000 Medium

   Identifying XPNPEP2 as the gene encoding membrane-bound aminopeptidase P at Xq25 established the molecular basis for a previously characterized enzymatic activity that cleaves Xaa-Pro bonds in bradykinin.

   Evidence Chromosomal mapping with somatic cell hybrids, expression analysis in X-translocation carrier fibroblasts, and sequence homology to the pita bread-fold metallopeptidase family

   PMID:10871044 PMID:10894934

   Open questions at the time

   • No direct structural data for human XPNPEP2 protein
   • Mechanism of partial X-inactivation escape not resolved
   • Physiological substrates beyond bradykinin not systematically catalogued
2. 2005 High

   Linking the C-2399A upstream polymorphism to reduced plasma APP activity and ACE inhibitor-induced angioedema established XPNPEP2 as a pharmacogenomic determinant of bradykinin-mediated adverse drug reactions.

   Evidence Genome-wide microsatellite QTL linkage analysis, mutation screening, measured genotype analysis, and case-control association in angioedema patients

   PMID:16175507

   Open questions at the time

   • Causal mechanism by which the SNP reduces expression not yet defined
   • Contribution of other bradykinin-degrading enzymes to angioedema risk not quantified
3. 2010 High

   Demonstrating sex- and race-dependent effects of the XPNPEP2 C-2399A genotype on APP activity and angioedema risk revealed that genetic regulation of bradykinin catabolism is modified by non-genetic factors.

   Evidence Serum APP activity measurement and multivariate case-control analysis (169 cases, 397 controls) with sex and race stratification

   PMID:20625347

   Open questions at the time

   • Biological basis for lower APP activity in men versus women unknown
   • Interaction between XPNPEP2 genotype and hormonal regulation not tested
4. 2011 High

   Functional dissection of the XPNPEP2 promoter showed that HNF4 binds the C-2399A enhancer region and that the risk haplotype reduces transcriptional activity, providing a molecular mechanism for genotype-dependent variation in APP expression.

   Evidence Nested deletion luciferase reporter assays, HNF4 overexpression, and haplotype association with plasma APP activity and angioedema

   PMID:21898657

   Open questions at the time

   • Chromatin context and tissue-specific enhancer activity not examined in endogenous locus
   • Whether other transcription factors co-regulate this enhancer is unknown
5. 2017 Medium

   Showing that XPNPEP2 overexpression promotes invasion, migration, and EMT in cervical cancer cells extended XPNPEP2 function beyond peptide catabolism to a role in tumor metastasis.

   Evidence Overexpression in SiHa and HeLa cells, invasion/migration assays, EMT marker analysis, and xenograft mouse metastasis model

   PMID:28670957

   Open questions at the time

   • Whether the pro-metastatic effect requires aminopeptidase catalytic activity or a non-enzymatic mechanism is unresolved
   • Downstream signaling pathways linking XPNPEP2 to EMT not identified
6. 2026 High

   Demonstrating that XPNPEP2 is essential for endothelial angiogenesis through physical interaction with SLC25A6 and protection from SIAH1-mediated degradation revealed a non-catalytic, mitochondria-protective function distinct from its aminopeptidase activity.

   Evidence XPNPEP2 KO mouse, shRNA knockdown in ECs, co-immunoprecipitation of XPNPEP2–SLC25A6, SIAH1 ubiquitin degradation assay, mitochondrial function assays, and in vivo wound healing/tumor growth models

   PMID:41573684

   Open questions at the time

   • Whether the aminopeptidase catalytic domain is required for SLC25A6 binding is unknown
   • How a GPI-anchored surface protein accesses mitochondrial SLC25A6 is mechanistically unclear
   • Independent replication of the XPNPEP2–SLC25A6 interaction in other labs is pending

• How XPNPEP2 integrates its dual roles as a bradykinin-degrading aminopeptidase and a non-enzymatic regulator of mitochondrial function in endothelial cells remains unresolved, as does whether its pro-metastatic activity is catalytic or structural.
• No structural data for human XPNPEP2 protein to map interaction surfaces
• Mechanism by which a GPI-anchored surface protein contacts intracellular SLC25A6 not defined
• Relative contributions of enzymatic versus scaffolding functions to in vivo phenotypes untested